Document:

Exhibit

EXHIBIT 4.1

DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934
As of December 28, 2019, Fossil Group, Inc. (the “Company,” “we,” “us,” and “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, $0.01 par value per share (“Common Stock”). The Common Stock is listed on The Nasdaq Stock Market LLC under the symbol “FOSL.”
Description of Capital Stock
The following is a description of the material terms of our capital stock. It does not purport to be complete and is subject to and qualified in its entirety by our Third Amended and Restated Certificate of Incorporation, or any supplement or amendment thereto (the “Certificate of Incorporation”), our Fifth Amended and Restated Bylaws, or any supplement or amendment thereto (the “Bylaws”), and the General Corporation Law of the State of Delaware (“DGCL”). Copies of the Certificate of Incorporation and Bylaws have been filed with the Securities and Exchange Commission as Exhibits 3.1, 3.2 and 3.3 to our Annual Report on Form 10-K.
Authorized Capital Stock
Under the Certificate of Incorporation, our authorized capital stock consists of:
		
	•
	100,000,000 shares of Common Stock; and

		
	•
	1,000,000 shares of undesignated preferred stock, par value $0.01 per share (“Preferred Stock”). 

As of December 28, 2019, we had 50,516,477 shares of Common Stock outstanding and no shares of Preferred Stock issued or outstanding. As of December 28, 2019, we had reserved approximately 10,288,468 additional shares of Common Stock for issuance under our long-term incentive plan. 
Common Stock
The holders of Common Stock are entitled to one vote per share on all matters submitted to a vote of the stockholders.  Unless otherwise required by law, the Certificate of Incorporation or the Bylaws, any question brought before any meeting of stockholders shall be decided by the vote of the holders of a majority of the stock present in person or represented by proxy and entitled to vote thereat. Each member of our board of directors (the “Board”) shall be elected by the vote of the majority of the votes cast with respect to the director. Cumulative voting of shares of Common Stock is prohibited.  
The holders of Common Stock are entitled to receive ratably such dividends, if any, as may be declared from time to time by the Board out of funds legally available therefor, subject to the payment of any preferential dividends with respect to any Preferred Stock that from time to time may be outstanding.  In the event of the liquidation, dissolution or winding up of the Company, the holders of Common Stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of the holders of any outstanding Preferred Stock. The holders of Common Stock have no preemptive or conversion rights or other subscription rights, and there are no redemptive or sinking fund provisions applicable to the Common Stock. All of the outstanding shares of Common Stock are fully paid and nonassessable.  The rights, preferences and privileges of the holders of Common Stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of Preferred Stock that the Board may designate in the future.
Preferred Stock
The Board, without further action by the stockholders, is authorized to fix and determine as to any series of Preferred Stock any and all of the relative rights and preferences of shares in such series, including, without limitation, preferences, limitations or relative rights with respect to redemption rights, conversion rights, voting rights, dividend rights and preferences on liquidation.  
Certain Provisions of the Certificate of Incorporation and Bylaws
The Certificate of Incorporation and Bylaws of the Company contain certain provisions that may delay, defer or prevent a change in control of the Company.

Issuance of Common or Preferred Stock
As indicated above, the Certificate of Incorporation gives the Board the authority, without further action by the stockholders, to issue from time to time Preferred Stock in one or more series and to fix the number of shares, designations, preferences and relative, participating, optional or other special rights and the qualifications, limitations or restrictions on the Preferred Stock. The issuance of, or the right to issue, Preferred Stock could have anti-takeover effects.
Any issuance of Common Stock or Preferred Stock with voting rights could, under certain circumstances, have the effect of delaying or preventing a change in control of the Company by increasing the number of outstanding shares entitled to vote and by increasing the number of votes required to approve a change in control. Shares of voting or convertible Preferred Stock could be issued, or rights to purchase such shares could be issued, to render more difficult or discourage an attempt to obtain control of the Company by means of a tender offer, proxy contest, merger or otherwise. Such issuances could therefore deprive stockholders of benefits that could result from such an attempt, such as the realization of a premium over the market price. Moreover, the issuance of additional shares of Common Stock or Preferred Stock to persons friendly to the Board could make it more difficult to remove incumbent management and directors from office even if such change were to be favorable to stockholders generally.
Number of Directors and Vacancies and Removal of Directors
Our Bylaws provide that the number of directors shall be fixed and determined from time to time by resolution adopted by the Board. Our Bylaws also provide that if a proposal to remove a Board member is properly brought before a meeting of the stockholders, a Board member may be removed by the vote of the holders of a majority of the stock present in person or represented by proxy and entitled to vote thereat. Any vacancy on the Board may be filled by the majority vote of the directors then in office, though less than a quorum.
Advance Notice
The Company’s Bylaws establish advance notice procedures with regard to stockholder nomination or removal of persons for election to the Board or other business to be brought before meetings of stockholders of the Company. These procedures provide that notice of such stockholder nominations or proposals must be timely given in writing to the Secretary of the Company prior to the meeting at which the action is to be taken.  The notice must contain certain information specified in the Bylaws.  To be timely in connection with an annual meeting, the notice must be received between 90 and 120 days prior to the date on which the immediately preceding year’s annual meeting of stockholders was held.  If the date of the annual meeting is 30 days earlier or more than 60 days later than such anniversary date, notice must be received no earlier than 120 days before the meeting and no later than the later of (i) 90 days before the meeting or (ii) the 10th day following the day on which the public announcement of the date of the annual meeting is first made by the Company. To be timely in connection with a special meeting, the notice must be received no earlier than 120 days before the meeting and no later than the later of (i) 90 days before the meeting or (ii) the 10th day following the day on which the public announcement of the date of the special meeting is first made by the Company. An adjournment or postponement of an annual or special meeting does not commence a new time period for the giving of notice. With respect to stockholder nominations of directors and stockholder proposals relating to the removal of directors, in addition to complying with the procedures set forth in the Bylaws, a stockholder who wishes to include such business in a proxy statement prepared by the Company must also comply with Rule 14a-8 under the Exchange Act, as the same exists or may hereafter be amended or any other applicable laws as presently or hereafter in effect.
Bylaw Amendments
The Company’s Bylaws require that any action taken by the Board to alter, amend or repeal the Bylaws or adopted new Bylaws be approved by the affirmative vote of at least 80% of all directors then in office, subject to repeal or change by the affirmative vote of the holders of at least 80% of the voting power of all outstanding shares of capital stock of the Company entitled to vote in the election of directors, voting together as a single class. 
Special Meetings of Stockholders  
Special meetings of stockholders may be called only by the Chairman of the Board, the President, at the request in writing of a majority of the Board of Directors or on the written request of holders of at least 50% of the total number of shares of capital stock of the Company issued and outstanding and entitled to vote.

Section 203 of DGCL 
The Company is a Delaware corporation and is subject to Section 203 of the DGCL.  In general, subject to certain exceptions, Section 203 prohibits a Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years following the date that such stockholder became an interested stockholder, unless (i) prior to such date the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder or (ii) upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced (excluding for purposes of determining the number of shares outstanding those shares owned by (x) persons who are directors and also officers and (y) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer), or (iii) on or subsequent to such date the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder.  Section 203 defines a “business combination” to include certain mergers, consolidation, asset sales and stock issuances and certain other transactions resulting in a financial benefit to an “interested stockholder.”  In addition, Section 203 defines an “interested stockholder” to include any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with such an entity or person.
Limitation of Liability of Directors
The Certificate of Incorporation generally provides that, to the fullest extent permitted by the DGCL, no director shall be liable to the Company or its stockholders for monetary damages for breach of certain fiduciary duties as a director. Under the DGCL, a director’s liability may not be eliminated:
		
	•
	for any breach(es) of the director’s duty of loyalty to us or to our stockholders;

		
	•
	for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;

		
	•
	for certain unlawful dividend payments or stock redemptions or repurchases; and

		
	•
	for any transaction from which the director derives an improper personal benefit.

The effect of this provision is to restrict the rights of the Company and its stockholders to recover monetary damages against a director for breach of certain fiduciary duties as a director.Exhibit 10.1

 

AMENDED
AND RESTATED TECHCARE CORP.

COMMON
STOCK PURCHASE AGREEMENT

 

This
Amended and Restated Common Stock Purchase Agreement (this “Agreement”) is dated as of February 23, 2020 and
amends and restates the Common Stock Purchase Agreement dated January 6, 2020, and is among (1) TechCare Corp., a Delaware corporation
(the “Company”), (2) the Company’s directors and (3) Citrine S A L Investment & Holdings Ltd. and
those of its affiliates listed in Appendix A hereto (together, “Investor”).

 

SECTION
1: SALE AND ISSUANCE

 

	1.1	Sale
    and Issuance of Shares. Subject to the terms and conditions of this Agreement, Investor agrees to purchase, and the Company
    agrees to sell and issue to Investor, up to 893,699,276 shares of the Company’s common stock, par value $0.0001 per
    share (the “Common Stock”), with such exact amount to be designated by the Investor at the Pre-Closing
    or Closing (as hereinafter defined), which represents up to 95% of the fully diluted capital stock of the Company as of immediately
    following the Closing (the “Shares”), at an aggregate purchase price of $150,000 (the “Purchase
    Price”). The Purchase Price must be paid in cash. The maximum number of shares that may be issued to Investor will
    be adjusted as necessary such that it represents 95% of the fully diluted capital stock of the Company as of immediately following
    the Closing.
	 	 
	1.2	Use
    of Proceeds. it is hereby agreed that the Purchase Price, of which $45,000 shall be paid following the Pre-Closing and
    $105,000 shall be paid at the Closing, shall be transferred by the Company to its subsidiary, Novomic, immediately following
    the payment to the Company thereof and following deduction of amounts to pay any expenses associated with Novomic. Neither
    the Company and/or Citrine (and/or any others on each of their behalf) shall have any right, claim and/or demand towards Novomic
    (and/or any others on its behalf) regarding the transfer and utilization of such funds, as aforesaid in this Section 1.2.

 

SECTION
2: CLOSING DATES AND DELIVERY

 

2.1

 

	a.	Pre-Closing.
    At Investor’s option, the purchase, sale and issuance of a number of the Shares that will be notified by the Investor
    to the Company not exceeding 452,963,196 (the “Pre-Closing”) shall take place as soon as practicable after
    the signing of this Agreement, provided that all the following conditions to the Pre-Closing are satisfied or waived by the
    Investor:

 

	 	1.	Letters
    of resignation of all the members of the board of directors of the Company, effective upon the Pre-Closing, have been delivered
    to the Company and to counsel to the Investor, and the board of the Company has approved the appointment, effective upon the
    Pre-Closing, of a new board nominated by Investor; and
	 	 	 
	 	2.	The
    board of the Company has resolved to change the signatory rights in all Company bank accounts to Citrine’s nominees,
    effective upon the Pre-Closing.

 

Without
derogating from Section 3, the Company and each of its directors hereby represent and warrant to Investor that the following shall
be true and correct in all material respects as of the date of the Pre-Closing, and that they shall be jointly and severally liable
in respect of a breach of these representations and warranties, all subject to the performance of all of the Investor’s
undertakings and obligations hereunder:

 

	 	1.	There
    are no material actions, suits, proceedings or investigations pending against the Company or Novomic (nor has the Company
    or any of its subsidiaries received written notice of any threat thereof) before any court or governmental agency. Neither
    the Company nor Novomic is a party or subject to the provisions of any material order, writ, injunction, judgment or decree
    of any court or government agency or instrumentality.
	 	 	 
	 	2.	Other
    than ongoing liabilities required by applicable State or Federal law and/or the OTCQB stock exchange, there are no material
    liabilities or obligations of the Company of any kind whatsoever, whether accrued, contingent, absolute, determined, determinable
    or otherwise. All expenses associated with Novomic after the Pre-Closing, including reporting expenses, will be borne by Novomic
    and not by the Company. Investor may deduct from the Purchase Price amounts to pay any expenses associated with Novomic.

 

    	 

    	 

    

 

At
the Pre-Closing, the Company’s transfer agent will confirm to the Investor that Shares in the number notified by the Investor
have been issued to the recipients listed in Appendix A hereto as will be set forth therein, and in conjunction therewith, the
Investor will immediately transfer to the Company’s bank account, or any other account designate by the Company, $45,000
in cash. Immediately following such transfer, the Company shall transfer such sum to Novomic and the Investor (including any others
on its behalf including its nominees to the Company’s Board) will perform any action and sign any documents required to
approve and effectuate such transfer to Novomic.

 

b.
Closing. Upon the satisfaction or waiver of all the conditions to the Closing set forth in Section 6, or on such later date
as the Company and the Investor shall mutually agree (the “Closing Date”), a number of Shares that will be
notified by the Investor to the Company that does not cause the Investor’s holding to exceed 95% of the fully diluted capital
stock of the Company as of immediately following the Closing shall be purchased, sold and issued (the “Closing”).
At the Closing, the Company’s transfer agent will confirm to the Investor that the notified number of the Shares have been
issued to the recipients listed in Appendix A hereto as will be set forth therein, and in conjunction therewith, the Investor
will immediately transfer to Novomic’s bank account, or any other such account as designated by Oren Traitsman, the second
portion of the Purchase Price, or $105,000. Each party to this Agreement shall work expeditiously and in good faith to procure
the satisfaction of all the conditions to Closing set forth in Section 6 of this Agreement.

 

SECTION
3: REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

The
Company and each of its directors hereby represent and warrant to Investor as follows, and shall each be jointly and severally
liable in respect of a breach of these representations and warranties:

 

3.1
Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing
under the laws of the State of Delaware and has the requisite corporate power and authority to execute and deliver this Agreement
and all other documents required to be executed and delivered by the Company in connection with this Agreement (collectively,
with the Agreement, the “Transaction Documents”), to perform its obligations hereunder and thereunder, and
to issue and deliver the Shares and has taken all necessary corporate action to authorize the execution, delivery and performance
of the Transaction Documents.

 

3.2
Subsidiary. As of the Closing, subject to section 2.1 hereof, the Company will own 10% of the fully diluted capital stock
of Novomic Ltd., an Israeli company (“Novomic”), and has divested, all other holdings in Novomic (the “Novomic
Divestment”). The Company will have obtained all necessary authorizations, including without limitation corporate, shareholder
and other approvals for the Novomic Divestment. Novomic is duly organized, validly existing and in good standing under the laws
of Israel. If for any reason the Closing occurs prior to completion of the Novomic Divestment, the Company will not be obliged
to bear any costs associated with Novomic.

 

3.3
Capitalization.

 

(a)
As of the date of this Agreement, the authorized capital stock of the Company consists of 500,000,000 shares of Common Stock,
of which 46,725,260 shares are issued and outstanding, and 50,000,000 shares of Preferred Stock, par value $0.0001 per share,
of which no shares are issued and outstanding. As of immediately following the Closing, the authorized capital stock of the Company
will consist of 1,500,000,000 shares of Common Stock, and 50,000,000 shares of Preferred Stock, par value $0.0001 per share, none
of which will be issued and outstanding. The Shares shall have the rights, preferences, privileges and restrictions set forth
in the Company’s Certificate of Incorporation as currently in effect (the “Charter”). The Company has
made available to Investor the Charter as an attachment to its SEC filing on Form 10K of March 28, 2019, and no steps have been
taken by the board of directors or any stockholder of the Company to authorize or effect any amendment or other modification to
the Charter except to effect the change from 500,000,000 to 1,500,000,000 shares of Common Stock in the authorized capital stock
of the Company.

 

    	 

    	 

    

 

(b)
As of the date of this Agreement, there are outstanding options to purchase 311,544 shares of Common Stock, and there are no outstanding
warrants. As of the Closing, there are no options, warrants, convertible securities or other rights, agreements or arrangements
to purchase any of the Company’s authorized and unissued capital stock and no shares of capital stock of the Company are
reserved for issuance, except for 311,544 options to purchase shares of Common Stock and an aggregate of 2,000,000 shares of Common
Stock of the Company reserved for issuance pursuant to the Company’s 2018 Stock Incentive Plan. The Company is not subject
to any agreement, arrangement or other obligation with respect to the registration of any securities of the Company.

 

(c)
All issued and outstanding shares of the Company’s capital stock (i) have been duly authorized and validly issued and are
fully paid and non-assessable, and (ii) were issued in compliance with all applicable state and federal laws concerning the issuance
of securities.

 

(d)
As of the Closing, the Company has reserved the Shares for issuance pursuant to this Agreement. The Shares, when issued and delivered
and paid for in compliance with the provisions of this Agreement, will be validly issued, fully paid and non-assessable. The Shares
will be free of any preemptive or similar rights, taxes, charges, liens or encumbrances.

 

3.4
Authorization.

 

All
corporate action on the part of the Company and its directors, officers and stockholders necessary for the authorization, execution
and delivery of each of the Transaction Documents by the Company, the authorization, sale, issuance and delivery of the Shares,
the Novomic Divestment, and the performance of all of the Company’s obligations under each of the Transaction Documents
has been taken or will be taken prior to the Closing. Each of the Transaction Documents constitutes valid and binding obligations
of the Company, enforceable in accordance with their terms.

 

3.5
No Conflict.

 

	(a)	The
    execution and delivery by the Company of this Agreement, the execution and delivery by the Company of each of the other Transaction
    Documents to which it is or will be a party do not, and the consummation by the Company of the transactions contemplated hereby
    and thereby will not, conflict with, or result in any violation of or constitute a default (with or without notice or lapse
    of time, or both) under, or give rise to a right of termination, cancellation or acceleration of any obligation or the loss
    of a material benefit under, or the creation of any lien or encumbrance pursuant to (i) any provision of the certificate of
    incorporation or bylaws or comparable organizational documents of the Company or Novomic, or (ii) any judgment, order, decree,
    statute, law, ordinance, rule or regulation applicable to the Company or Novomic or Novomic’s properties or assets,
    except in the case of clause (ii), which would not materially impair the Company’s ability to fulfill its obligations
    under the Transaction Documents or have a material effect on the business or operations of the Company and Novomic, taken
    as a whole.
	 	 
	(b)	No
    consent, approval, order or authorization of, notice to, or registration, declaration or filing with any court, administrative
    agency or commission or other governmental authority or instrumentality, domestic or foreign, including any industry self-regulatory
    organization (a “governmental authority”) is required by or with respect to the Company or Novomic in connection
    with the execution and delivery by the Company of this Agreement or any of the Transaction Documents or the consummation by
    the Company of the transactions contemplated hereby and thereby, except for any required notices of sale of securities filed
    with the U.S. Securities and Exchange Commission (“SEC”) and state securities agencies.

 

3.6
SEC Filings.

 

	(a)	The
    Company has made available to Investor through the SEC’s website all of its periodic reports, statements, schedules
    and registration statements filed with the SEC since August 4, 2010 (the documents referred to in this Section 3.6(a), collectively,
    the “SEC Filings”).

 

    	 

    	 

    

 

	(b)	Since
    August 4, 2010, the Company has filed with or furnished to the SEC each report, statement, schedule, form or other document
    or filing required by applicable law to be filed or furnished at or prior to the time so required. As of its filing date,
    each SEC Filing complied as to form in all material respects with the applicable requirements of the Securities Act of 1933,
    as amended (the “Securities Act”) and the Securities Exchange Act of 1934, as amended (the “Exchange
    Act”), as the case may be and the SEC Filings do not contain any untrue statement of a material fact or omit to
    state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which
    they were made, not misleading.

 

3.7
Financial Statements. The audited consolidated financial statements and unaudited condensed consolidated financial statements
of the Company included in the SEC Filings (i) comply as to form, as of their respective filing dates with the SEC, in all material
respects with the applicable accounting requirements and the published rules and regulations of the SEC with respect thereto,
(ii) have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) applied on
a consistent basis during the periods involved (except, in the case of unaudited statements, for the absence of footnotes), and
(iii) fairly present the consolidated financial position of the Company and its consolidated subsidiaries as of the dates thereof
and their consolidated results of operations and cash flows for the periods then ended (subject to normal year-end adjustments
in the case of any unaudited interim financial statements).

 

3.8
No Material Undisclosed Liabilities. Other than those required by applicable State or Federal law and/or the OTCQB stock exchange,
there are as of the Closing no material liabilities or obligations of the Company of any kind whatsoever, whether accrued, contingent,
absolute, determined, determinable or otherwise. To the company’s knowledge as of the signing of this Agreement, the Company
has no outstanding tax liabilities.

 

3.9
Contracts and Assets. As of the Closing, except for its holding of 10% of the capital stock of Novomic, the Company is not
a party to any contracts, agreements or instruments, and has no properties or assets, and except for its holding of 10% of the
capital stock of Novomic, the Company has no subsidiaries and has no interest in any other company. The Company does not have
a “poison pill” or similar shareholder rights plan in effect. All contracts to which the Company has at any time been
a party (“Former Contracts”) have as of the Closing been terminated or expired and there are no outstanding
debts, obligations, restrictions or liabilities of the Company or any other party under any Former Contracts.

 

3.10
Compliance. The Company is not in violation (i) of any term of its certificate of incorporation or bylaws, each as amended,
or (ii) of any federal or state statutes, rules or regulations the violation of which would be material to the business or operations
of the Company and Novomic, taken together as a whole.

 

3.11
Litigation. There are no material actions, suits, proceedings or investigations pending against the Company or Novomic (nor
has the Company or any of its subsidiaries received written notice of any threat thereof) before any court or governmental agency.
Neither the Company nor Novomic is a party or subject to the provisions of any material order, writ, injunction, judgment or decree
of any court or government agency or instrumentality.

 

3.12
Offering. Subject to the accuracy of Investor’s representations and warranties in Section 4, none of the Company, any
of its affiliates, or any person or entity acting on its behalf has, directly or indirectly, made any offers or sales of any security
or solicited any offers to buy any security, under circumstances that would require registration of the issuance of any of the
Shares under the Securities Act, whether through integration with prior offerings or otherwise.

 

3.13
Registration Rights. The Company is presently not under any obligation and has not granted any rights to register under the
Securities Act any of its presently outstanding securities or any of its securities that may hereafter be issued.

 

3.14
Brokers or Finders. The Company has not incurred, and will not incur, directly or indirectly, as a result of any action taken
by the Company, any liability for brokerage or finders’ fees or agents’ commissions or any similar charges in connection
with any of the Transaction Documents or any of the transactions contemplated hereby and thereby.

 

3.15
Employees and Service Providers. As of the Closing the Company has no employees or service providers and has no outstanding
obligations or liabilities to any former employees or service providers.

 

3.16
Representations Complete. None of the representations or warranties made by the Company in this Agreement contains any untrue
statement of a material fact or omits to state any material fact necessary in order to make the statements contained herein, in
the light of the circumstances under which they were made, not misleading.

 

    	 

    	 

    

 

SECTION
4: REPRESENTATIONS AND WARRANTIES OF INVESTOR

 

Investor
hereby represents and warrants to the Company as follows:

 

4.1
Organization, Good Standing and Qualification. Investor is a company duly organized and validly existing under the laws of
Israel. Investor has the requisite corporate power and authority to execute and deliver each of the Transaction Documents to which
it is a party and to perform its obligations pursuant to the Transaction Documents.

 

4.2
Authorization. All corporate action on the part of Investor and its directors, officers and stockholders necessary for the
authorization, execution and delivery of each of the Transaction Documents to which it is a party by Investor and the performance
of all of Investor’s obligations under each of the Transaction Documents has been taken or will be taken prior to the Closing.
Each of the Transaction Documents to which it is a party constitutes valid and binding obligations of Investor, enforceable in
accordance with their terms.

 

4.3
No Conflict.

 

	(a)	The
    execution and delivery by Investor of this Agreement, and the execution and delivery by Investor of each of the other Transaction
    Documents to which it is or will be a party do not, and the consummation by Investor of the transactions contemplated hereby
    and thereby will not, conflict with, or result in any violation of, or constitute a default (with or without notice or lapse
    of time, or both) under, or give rise to a right of termination, cancellation or acceleration of any obligation or the loss
    of a material benefit under, or the creation of any lien or encumbrance pursuant to (i) any provision of the certificate of
    incorporation or bylaws or comparable organizational documents of Investor, or (ii) any loan or credit agreement, note, mortgage,
    indenture, lease or other agreement, obligation or instrument to which Investor or any of its subsidiaries is a party or by
    which their respective properties or assets may be bound, or (iii) any law, permit, concession, franchise, license, judgment,
    order, decree, statute, law, ordinance, rule or regulation applicable to Investor or its properties or assets; except, in
    each case, for any of the foregoing which would not have a material and adverse effect on Investor’s ability to fulfill
    its obligations under the Transaction Documents.
	 	 
	(b)	 No
    consent, approval, order or authorization of, notice to, or registration, declaration or filing with any governmental authority
    is required by or with respect to Investor in connection with the execution and delivery by Investor of this Agreement or
    any of the Transaction Documents to which it is a party or the consummation by Investor of the transactions contemplated hereby
    and thereby.

 

4.4
Private Placement. Investor is acquiring the Shares for investment for its own account, not as a nominee or agent, and not
with the view to, or for resale in connection with, any distribution thereof. Investor has such knowledge and experience in financial
and business matters so that Investor is capable of evaluating the merits and risks of its investment in the Company. Investor
is an “accredited investor” within the meaning of Regulation D, Rule 501(a), promulgated by the SEC under the Securities
Act.

 

4.5
Legends. Investor understands and agrees that the Shares or any other securities issued in respect of the Shares upon any
stock split, stock dividend, recapitalization, merger, consolidation or similar event, shall bear the following legend and that
the transfer agent for the Company may be instructed that the Shares are subject to the terms of such legend:

 

“THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES
LAWS OF ANY STATE, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SUCH
ACT AND/OR APPLICABLE STATE SECURITIES LAWS, OR UNLESS SUCH REGISTRATION IS NOT REQUIRED.”

 

4.6.
Novomic Divestment. After the Pre-Closing, the Investor shall not take any actions to amend, violate or obstruct the agreements
governing the Novomic Divestment without the consent and agreement of Novomic.

 

    	 

    	 

    

 

SECTION
5: RESERVED

 

SECTION
6: CONDITIONS TO CLOSING

 

6.1
Conditions to the Obligations of Investor. Investor’s obligation to purchase the Shares at the Closing is subject to
the fulfillment on or before the Closing of each of the following conditions, unless otherwise waived in writing by Investor:

 

	(a)	Representations
    and Warranties. The representations and warranties made by the Company and its directors in Section 3 shall be true and
    correct in all material respects as of the date hereof and as of the Closing Date as though made as of the Closing Date, except
    to the extent such representations and warranties are made only as of an earlier date, in which case as of such earlier date
    (in each case, disregarding any standards of materiality contained in such representations and warranties).

 

6.2
Conditions to the Obligations of the Company.

 

	 	The
    Company’s obligation to sell and issue the Shares at the Closing is subject to the fulfillment on or before such Closing
    of the following conditions, unless otherwise waived in writing by the Company:
	 	 
	(a)	The
    representations and warranties made by Investor in Section 4 shall be true and correct in all material respects as of the
    date hereof and as of the Closing Date as though made as of the Closing Date, except to the extent such representations and
    warranties are made only as of an earlier date, in which case as of such earlier date (in each case, disregarding any standards
    of materiality contained in such representations and warranties).
	 	 
	(b)	At
    the Closing, the Company will be clear of all operations and subsidiaries except for a 10% holding in Novomic and that the
    Company shall have not otherwise failed to perform any of its rights or obligations as set forth in the documents and agreements
    governing the Novomic Divestment. 

 

SECTION
7: MISCELLANEOUS

 

7.1
Amendment; Waiver. Except as expressly provided herein, neither this Agreement nor any term hereof may be amended, waived,
discharged or terminated other than by a written instrument referencing this Agreement and signed by each of the Company and Investor.

 

7.2
Notices. All notices and other communications required or permitted hereunder shall be in writing and shall be mailed by registered
or certified mail, postage prepaid, sent by facsimile or otherwise delivered by hand, messenger or courier service addressed:

 

	(a)	if,
    to Investor, to: Citrine S A L Investment & Holdings Ltd, 3 Ha’Melacha St., Tel Aviv, Israel
	 	 
	 	with
        a copy (which shall not constitute notice) to:

        Pearl
        Cohen Zedek Latzer Baratz

        Azrieli
        Sarona Tower

        121
        Menachem Begin Rd.

        Tel-Aviv,
        6701203, Israel

        Attn:
        Ilan Gerzi, Adv.

	 	 
	(b)	if,
    to the Directors, to: Novomic Ltd., 23 Ha'melacha Street Rosh Haayin, 4809173 Israel
	 	 
	 	with
        a copy (which shall not constitute notice) to:

        Zysman,
        Aharoni, Gayer and Sullivan & Worcester LLP

        1633
        Broadway

        New
        York, NY 10019

        Attn:
        Oded Har-Even, Esq.

 

    	 	 	 

    	 

    

 

	(c)	if,
    to the Company, to its registered address from time to time
	 	 
	 	with
        copies (which shall not constitute notice) to:

        Zysman,
        Aharoni, Gayer and Sullivan & Worcester LLP

        1633
        Broadway

        New
        York, NY 10019

        Attn:
        Oded Har-Even, Esq.

         

        and

         

        Pearl
        Cohen Zedek Latzer Baratz

        Azrieli
        Sarona Tower

        121
        Menachem Begin Rd.

        Tel-Aviv,
        6701203, Israel

        Attn:
        Ilan Gerzi, Adv.

 

Each
such notice or other communication shall for all purposes of this Agreement be treated as effective or having been given when
delivered, or if sent via an internationally-recognized overnight courier service, freight prepaid, specifying next-business-day
delivery, one business day after deposit with the courier, or (ii) if sent via mail, at the earlier of its receipt or five days
after the same has been deposited in a regularly-maintained receptacle for the deposit of the United States mail, addressed and
mailed as aforesaid or (iii) if sent via facsimile, upon confirmation of facsimile transfer.

 

7.3
Governing Law. This Agreement shall be governed by the laws of Israel and any dispute arising from or in connection with this
Agreement shall be subject to the exclusive jurisdiction of the courts of Israel. No other forum shall have jurisdiction.

 

7.4
Expenses. Except as expressly provided herein, the Company and Investor shall each pay their own expenses in connection with
the transactions contemplated by this Agreement and the other Transaction Documents.

 

7.5
Survival. The representations, warranties, covenants and agreements made in this Agreement shall survive any investigation
made by any party hereto and the closing of the transactions contemplated hereby.

 

7.6
Successors and Assigns. This Agreement, and any and all rights, duties and obligations hereunder, shall not be assigned, transferred,
delegated or sublicensed by either party hereto without the prior written consent of the other party. Any attempt by any such
party to assign, transfer, delegate or sublicense any rights, duties or obligations that arise under this Agreement in violation
of this Section 7.6 shall be null and void ab initio. Subject to the foregoing and except as otherwise provided herein, the provisions
of this Agreement shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators
of the parties hereto.

 

7.7
Entire Agreement. This Agreement and the other Transaction Documents, including the exhibits attached hereto and thereto,
constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof.
No party shall be liable or bound to any other party in any manner with regard to the subjects hereof or thereof by any warranties,
representations or covenants except as specifically set forth herein or therein.

 

    	 	 	 

    	 

    

 

7.8
Delays or Omissions. Except as expressly provided herein, no delay or omission to exercise any right, power or remedy accruing
to any party to this Agreement upon any breach or default of any other party under this Agreement shall impair any such right,
power or remedy of such non-defaulting party, nor shall it be construed to be a waiver of any such breach or default, or an acquiescence
therein, or of or in any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default
be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval
of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of
any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically
set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party to this Agreement,
shall be cumulative and not alternative.

 

7.9
Severability. If any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal,
unenforceable or void, portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed
from this Agreement, and such court will replace such illegal, void or unenforceable provision of this Agreement with a valid
and enforceable provision that will achieve, to the extent possible, the same economic, business and other purposes of the illegal,
void or unenforceable provision. The balance of this Agreement shall be enforceable in accordance with its terms.

 

7.10
Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be enforceable against the
parties actually executing such counterparts, and all of which together shall constitute one instrument.

 

7.11
Public Announcements. The text of any public announcement made in connection with this Agreement, including any report
to the SEC made in connection with the signing hereof, shall be approved in advance by Investor.

 

(signature
page follows)

 

    	 	 	 

    	 

    

 

The
parties are signing this Common Stock Purchase Agreement as of the date stated in the introductory clause.

 

	                     	 
	TechCare
    Corp.	 
	By:	 	 
	Name:	 	 
	Title:	 	 
	 	 	 
	 	 
	Oren
    Traistman, director of TechCare Corp.	 
	 	 	 
	 	 
	Yossef
    De-Levy, director of TechCare Corp.	 
	 	 	 
	 	 
	Citrine
    S A L Investment & Holdings Ltd.	 
	By:	 	 
	Name:	             	 
	Title:	 	 

 

    	 	 	 

    	 

    

 

Appendix
A

 

Tables
of allocation of the Shares upon issuance

 

At
Pre-Closing:

 

	Name
    and details	Number
    of shares
	 	 
	 	 
	 	 

 

At
Closing:

 

	Name
    and details	Number
    of shares

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}]]